Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma.
Bendamustine
Hodgkin lymphoma
Pediatric
Pharmacokinetics
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
09
03
2023
accepted:
25
04
2023
medline:
14
6
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
The Stanford V chemotherapy regimen has been used to treat Hodgkin lymphoma (HL) patients since 2002 with excellent cure rates; however, mechlorethamine is no longer available. Bendamustine, a drug structurally similar to alkylating agents and nitrogen mustard, is being substituted for mechlorethamine in combination therapy in a frontline trial for low- and intermediate-risk pediatric HL patients, forming a new backbone of BEABOVP (bendamustine, etoposide, doxorubicin, bleomycin, vincristine, vinblastine, and prednisone). This study evaluated the pharmacokinetics and tolerability of a 180 mg/m Bendamustine plasma concentrations were measured in 118 samples from 20 pediatric patients with low- and intermediate-risk HL who received a single-day dose of 180 mg/m Bendamustine concentration vs time demonstrated a trend toward decreasing clearance with increasing age (p = 0.074) and age explained 23% of the inter-individual variability in clearance. The median (range) AUC was 12,415 (8,539, 18,642) µg hr/L and the median (range) maximum concentration was 11,708 (8034, 15,741) µg/L. Bendamustine was well tolerated with no grade 3 toxicities resulting in treatment delays of more than 7 days. A single-day dose of 180 mg/m
Identifiants
pubmed: 37199744
doi: 10.1007/s00280-023-04540-9
pii: 10.1007/s00280-023-04540-9
doi:
Substances chimiques
Bendamustine Hydrochloride
981Y8SX18M
Mechlorethamine
50D9XSG0VR
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-6Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Metzger ML, Billett A, Link MP (2012) The impact of drug shortages on children with cancer–the example of mechlorethamine. N Engl J Med 367(26):2461–2463
doi: 10.1056/NEJMp1212468
pubmed: 23268661
Wang ML et al (2022) Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 386(26):2482–2494
doi: 10.1056/NEJMoa2201817
pubmed: 35657079
Sehn LH et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6(2):533–543
doi: 10.1182/bloodadvances.2021005794
pubmed: 34749395
pmcid: 8791582
Ghia P et al (2020) ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 38(25):2849–2861
doi: 10.1200/JCO.19.03355
pubmed: 32459600
Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27(9):1492–1501
doi: 10.1200/JCO.2008.18.7252
pubmed: 19224851
Leoni LM (2011) Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 48(Suppl 1):S4-11
doi: 10.1053/j.seminhematol.2011.03.002
pubmed: 21530771
Korycka-Wolowiec A, Robak T (2012) Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 8(11):1455–1468
doi: 10.1517/17425255.2012.723690
pubmed: 22970741
Owen JS et al (2010) Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 66(6):1039–1049
doi: 10.1007/s00280-010-1254-8
pubmed: 20140617
pmcid: 2956859
Moon Y, E J, Garnett C, et al (2011) Clinical Pharmacology Review Document. https://www.022405orig1s000clinpharmr.pdf (fda.gov)
Jeha S et al (2021) Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer 127(12):2074–2082
doi: 10.1002/cncr.33465
pubmed: 33598942
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/22249s000_MedR_P1.pdf .
Moskowitz AJ et al (2013) Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 31(4):456–460
doi: 10.1200/JCO.2012.45.3308
pubmed: 23248254
Metzger M, Stanford V et al (2012) chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma results of a multi-institutional prospective clinical trial. J Clin Oncol 30(15):9502–9502
doi: 10.1200/jco.2012.30.15_suppl.9502
Rasschaert M et al (2007) A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. Br J Cancer 96(11):1692–1698
doi: 10.1038/sj.bjc.6603776
pubmed: 17486132
pmcid: 2359912